Organization | IDT Australia Ltd.

IDT Australia Ltd. Report issue

For profit Phase 1

Founded: Boronia Australia (1986)

Organization Overview

First Clinical Trial

2012

NCT01787747

First Marketed Drug

1986

aminophylline (aminophyllin)

First NDA Approval

None

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

CMAX | CMAX - A division of IDT Australia, Limited | CMAX, A Division of IDT Australia, Limited | CMAX (A division of IDT Australia Ltd) | CMAX - Clinical Research Pty Ltd, Level 5, 18a North Terrace, Adelaide, South Australia, 5000, Australia | CMAX Ltd | c/o CMAX - a division of IDT Australia Ltd. | IDT AUSTRALIA LTD | IDT CMAX | IDT CMAX Clinical Trials

Active Ingredients

Marketed Drugs (8)

aminophylline (aminophyllin) (1976)

carbidopa (sinemet) (1995)

dipyridamole (persantine) (1992)

levodopa (larodopa) (1995)

pindolol (visken) (1993)

prazosin (minipress) (1989)

procainamide (pronestyl) (1986)

temozolomide (temodar) (2016)

Drugs in Phase 1 Trials (20)

23-valent pneumococcal polysaccharide vaccine (pneumovax-23) (1 trial)

bevacizumab (avastin) (1 trial)

brii-297 (1 trial)

cellulose (1 trial)

deuterated dextromethorphan (2 trials)

dextromethorphan (delsym) (2 trials)

entecavir (baraclude) (1 trial)

Frunexian (1 trial)

gamma-pn3 (1 trial)

interferon beta-1b (betaseron) (1 trial)

memantine (namenda) (1 trial)

naltrexone (revia) (1 trial)

orelabrutinib (1 trial)

ots167 (1 trial)

pneumococcal 13-valent conjugate vaccine (prevnar 13) (1 trial)

pxs-5382a (1 trial)

quinidine (2 trials)

spr741 (1 trial)

ustekinumab (stelara) (1 trial)

Vonafexor (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Alzheimer Disease (Phase 1)

Hepatitis B (Phase 1)

Hepatitis B, Chronic (Phase 1)

Lupus Erythematosus, Systemic (Phase 1)

Multiple Sclerosis (Phase 1)

Overview

Highest Phase: Phase 1
# of Trials: 16
# of Trial APIs: 20